Endocrine Abstracts

Gestational Diabetes Mellitus (GDM) is characterized by insulin resistance accompanied byreduced beta-cell compensation to increased insulin demand, typically observed in the secondand third trimester and associated with adverse pregnancy outcomes. There is a need for abiomarker that can accurately diagnose GDM, predict onset and accurately monitor status, reducing foetal-maternal morbidity and mortality risks. To this end, circulating microRNAs(miRNAs) present themselves as p...

Background: Semaglutide is a glucagon-like peptide-1 receptor agonist (GLP-1-RA) whose role as a second-line treatment for patients with type 2 diabetes (T2D) has significantly increased. It has demonstrated cardiovascular safety and superiority in terms of glycaemic control and weight loss, compared to other GLP-1-RAs. The most common side effects are mild gastrointestinal, but it may also cause renal failure secondary to dehydration and an increased risk of diabetic retinopa...

Justification and objectives: Gestational Diabetes Mellitus (GDM) is associated with an increased risk of Pregnancy-Induced Hypertension (PIH). Previous studies suggest a relationship between inflammatory markers and the development of PIH and obstetric and perinatal complications. The aim of the study was to establish the relationship between pro and anti-inflammatory cytokines and the development of PIH and the impact on obstetric and perinatal outcomes.<p clas...

Introduction: Funding of continuous glucose monitoring (CGM) has been established by Madrid Health Service for adults with type1 Diabetes Mellitus (DM) who meet specific criteria. This has brought to lightthe need foran increasedinvestment in care time. In our Division, a structured training program has been established, consisting of 2 training sessions (TS); the first one based on basic contents to initiateFlash-CGM, and the second one, more intensive and targeted, focused o...

IntroductionNon-functioning secretory pituitary adenomas are usually characterized by the lack of associated hormone overproduction. The absence of symptoms of excess hormone production results in a delayed diagnosis: sometimes as an incidental diagnosis, sometimes due to compressive symptoms with visual involvement or neurological symptoms as headache. Howewer, hydrocephalus associating Hakim-Adams Syndrome caused by foramen of Monro obstruction seconda...

Introduction: Semaglutide is a GLP1 receptor agonist (GLP1RA) recently approved in Spain for the treatment of Type 2 Diabetes (T2D) and the National Health Service finances it for patients with T2D and body mass index (BMI) > 30 with a poor metabolic control with metformin.Objectives: Evaluate the effects of Semaglutide on glycemic control and body composition in patients with T2D (PwT2D) and obesity after 6 months of use in a real life setting.<...

Background: NAFLD(non–alcoholic fatty liver disease) includes; non–alcoholic fatty liver(NAFL), non–alcoholic steatohepatitis (NASH) and its complications (fibrosis, cirrhosis and hepatocellular carcinoma). These diseases are currently the most common cause of liver disease in western countries, due to the obesity and DM2 epidemic. There are scores that determine the risk of liver fibrosis in a non–invasive way.Aims: To determine ...

p53 family controls several metabolic and cellular functions. The p63 member regulates lipid metabolism in hepatocytes and contributes to the development of liver steatosis. Here we show that p63 plays an important role in liver fibrosis. P63 is upregulated in patients with NASH, correlating positively with fibrosis score and collagen 1a1 expression. P63 expression is also increased in different animal models of diet-induced NASH and chemically induced liver fibrosis. Mice wit...

BackgroundTherapeutic experience with SGLT2i is limited in the elderly. Its initiation is not recommended in patients over 85 years based on volume depletion risk. The aim of this study is to analyze clinical efficacy and safety of SGLT2i in elder T2DM patients.MethodsThis observational retrospective study included 544 T2DM subjects who initiated SGLT2i as add-on treatment between February 2018–2019 and ...

Introduction and objectivesSGT2i have changed the paradigm of T2DM management. Last guidelines insist on the importance of using newer glucose-lowering drugs with a demonstrated reduction in cardiovascular events (CVE). The aim of this study is twofold: to describe CVE, heart failure (HF) and renal function evolution; and to assess its efficacy in non-selected patients with T2DM initiating SGLT2iMaterial and methods<p class="ab...